Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist

European Journal of Clinical Investigation

Volumn 27, Issue 7, 1997, Pages 568-574

  Badimon, J J ^a   Meyer, B ^a   Feigen, L P ^b   Baron, D A ^c   Chesebro, J H ^a   Fuster, V ^a   Badimon, L ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Dept of Cardiovasc Dis Research ^*  (United States)

^c PFIZER INC   (United States)

^d CSIC   (Spain)

Author keywords

IIb IIIa receptor complex; Platelet aggregation; Platelets; Thrombosis; Xemilofiban

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; XEMILOFIBAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTICLE; CONTROLLED STUDY; DOG; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 0030878576     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1480697.x     Document Type: Article

References (36)

1. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation 1993;87:II3-II16.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50 and 310-18.
3. Pytele R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: a member of a family of RGD specific adhesion receptor. Science 1986;231:1559-62.
4. Philips DR, Charo IF, Scarborough RM. GP IIb/IIIa: the responsive integrin. Cell 1991;65:359-62.
5. Calvete JJ. Clues tor understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994;72:1-15.
6. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;68:783-6.
7. Hanson SR, Pareti FI, Ruggeri ZN et al. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81:149-54.
8. Topol EJ, Califf RW, Weisman HF et al. Randomised trial or coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
9. The Epic Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;14:956-61.
10. Ferguson JJ. Epilog and Capture trials halted because of positive interim results. Circulation 1996;93:637.
11. Kleiman NS, Osham M, Califf RM et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy; results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-9.
12. Ruggeri ZM, Houghton RA, Russel SR, Zimmerman TS. Inhibition of platelet function with synthetic peptide designed to be high affinity antagonist of fibrinogen to platelets. Proc Natl Acad Sci USA 1986;83:5708-12.
13. Gould RJ, Polokoff MA, Friedman PA et al. Disintegrins: a family of integrins inhibitory proteins from viper venoms. Proc Soc Exp Biol Chem 1990;195:168-71.
14. Shebuski RJ, Ramjit DR, Bencen GH, Polokoff MA. Characterization and platelet inhibitory activity of bitistatin, a potent RDGF-containing peptide from the venom of the viper Bitis arietans. J Biol Chem 1989;264:21550-6.
15. Savage B, Marzec UM, Chao BH, Harker LA, Maraganore JM, Ruggeri ZM. Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition sites on platelet glycoprotein IIb/IIIa complex inhibits receptor function. J Biol Chem 1990;265:11766-72.
16. Scarborough RM, Rose JW, Hsu MA et al. A GP IIb/IIIa specific integrin antagonist from the venom of Sistrarus M. barbouri. J Biol Chem 1991;266:9359-64.
17. Mousa SA, DeGrado WF, Mu DX, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa antagonist. Circulation 1996;93:537-43.
18. ISIS-2 Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2: 349-60.
19. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31.
20. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
21. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-75.
22. Nicholson N, Panzer-Knodle S, Salyers A et al. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation 1995;91:403-10.
23. Szalony J, Haas NF, Salyers A et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation 1995;91:411-16.
24. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition: ex vivo study in a swine model. Arteriosclerosis 1986;6:312-20.
25. Badimon L, Turitto VT, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biological and prosthetic materials. J Lab Clin Med 1987;110:706-18.
26. Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L. Arterial thrombosis induced by severely damaged arterial wall is inhibited by a boro-arginine synthetic peptide with antithrombin activity. Thromb Haemost 1994;71:511-17.
27. Meyer B, Badimon JJ, Mailhac A et al. Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation 1994;90:2432-8.
28. Galvez A, Badimon L, Badimon JJ, Fuster V. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost 1986;56:128-32.
29. Fernández-Ortiz, A, Badimon JJ, Falk E et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
30. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in non-parallel streamlines. Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989;84:1134-44.
31. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994;24:1091-4.
32. Baumgartner HR, Tschopp TB, Meyer D. Shear rate dependent inhibition of platelet adherence and aggregation on collagenous surfaces by antibodies to human factor VIII/vWillebrand factor. Br J Haematol 1980;44:127-39.
33. Turitto VT, Baumgartner HR. Initial deposition of platelets and fibrin on vascular surfaces in flowing blood. In: Golman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis. Basic principles and clinical practice, 3rd edn. Philadelphia: J.B. Lippincott Company, 1993;805-22.
34. Sixma JJ, Pronk A, Nievelstein PNEM et al. Platelet adhesion to extracellular matrices of cultured cells. Ann NY Acad Sci 1991; 614:181-92.
35. Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in GP IIb/IIIa, GP Ib and storage granules. Blood 1986;67:322-30.
36. Gallo R, Hayes R, Badimon L, Chesebro JH, Fuster V, Badimon JJ. The role of thrombosis in restenosis. In: Feuerstein GZ. ed. Coronary restenosis: from genetics to therapeutics. New York: Marcel Dekker, 1997;241-56.